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A b s t r a c t
Background: The determinants of the impact of mineralocorticoid receptor antagonism (MRA) on exercise tolerance in heart 
failure with reduced ejection fraction (HFrEF) have not been sufficiently characterised. 
Aim: We sought to investigate the factors associated with improvement in exercise capacity following the introduction of 
spironolactone to therapy in HFrEF patients, as well as to assess the association between improvement in exercise capacity 
and changes in cardiac functional characteristics with treatment.
Methods: In 120 patients (age 62 ± 11 years) with stable chronic HFrEF, remaining on optimal pharmacotherapy, spirono-
lactone 25 mg/d was added to treatment. Echocardiographic assessment, including myocardial deformation, and treadmill 
exercise tests were performed at baseline and at six-month follow-up. 
Results: According to the functional improvement at follow-up, patients were stratified into two groups: with increase in exercise 
capacity > 20% (IMPRpos, n = 68) and < 20% (IMPRneg, n = 52) of the baseline value. The IMPRpos subset demonstrated 
significantly larger improvement in left ventricular systolic and diastolic functions at follow-up, as assessed by global longitudinal 
deformation (GLS), ejection fraction, and tissue e’ velocity. Functional improvement > 20% was independently predicted by 
diabetes (odds ratio [OR] 5.62, p = 0.011), estimated glomerular filtration rate (OR 0.95, p = 0.008), and B-type natriuretic 
peptide (BNP) at baseline (OR 0.54, p = 0.027), and associated with increase in GLS at follow-up (OR 1.40, p = 0.019).
Conclusions: In patients with HFrEF, improvement in exercise capacity in response to the addition of spironolactone to 
treatment is more evident in the presence of diabetes, decreased renal function and lower BNP, and improvement in GLS is 
a contributor to this beneficial effect of MRA.
Key words: exercise capacity, heart failure with reduced ejection fraction, left ventricular longitudinal deformation,  
mineralocorticoid receptor antagonism
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INTRODUCTION
Mineralocorticoid receptor antagonism (MRA) has been 
extensively shown to decrease mortality and morbidity in 
heart failure (HF) with reduced ejection fraction (HFrEF), 
with a number of pathophysiological mechanisms mediat-
ing its treatment effects [1–4]. The HF guidelines endorse 
the addition of MRA as the next step in pharmacotherapy 
for HFrEF patients not responding satisfactorily to treatment 
with angiotensin converting enzyme inhibitors (ACEIs) or an-
giotensin receptor blockers (ARBs), b-blockers, and diuretics 
[5, 6]. The translation of evidence-based therapy to routine 
clinical practice is, however, suboptimal, because in some 
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registries the proportion of eligible patients not receiving MRA 
exceeds 60% [7]. The major reason discouraging physicians 
from prescribing MRA is the risk of renal dysfunction and 
hyperkalaemia as potential side effects. 
Despite the increasing use of MRA in HF, the factors influ-
encing the impact of this treatment on exercise tolerance have 
not been sufficiently studied. Better recognition of this issue 
may aid decision-making, especially in patients with renal 
disorders and/or the propensity to develop hyperkalaemia, 
who require a careful weighing of the benefits and risks as-
sociated with this therapy. Both hyperkalaemia and decreased 
renal function may coexist in HF patients and are frequently 
linked with older age, hypotension, and diabetes mellitus [8].
The improvement in left ventricular (LV) performance 
is a major component of the favourable impact of MRA on 
exercise tolerance in HF patients [9, 10]. Global longitudinal 
deformation (GLS) is a well-validated parameter of LV systolic 
function, which has been demonstrated as a sensitive and 
specific marker outperforming other measures of LV contractil-
ity, especially in early stages of HF and subclinical myocardial 
disease [11, 12]. Nonetheless, the diagnostic role of GLS in 
advanced cardiac impairment in HFrEF is less well established. 
Some evidence suggests that GLS is more closely associated 
with alterations in exercise capacity than LV ejection fraction 
(LVEF) [13, 14].
In this study, we sought to investigate the factors associ-
ated with improvement in exercise capacity following the 
introduction of spironolactone to therapy in patients with 
HFrEF to better characterise the subset with a high probability 
of functional benefit. We also sought the association between 
the improvement in exercise capacity and changes in cardiac 
functional characteristics with treatment, with special focus on 




The study population encompassed 120 patients with stable 
symptomatic heart failure in New York Heart Association 
(NYHA) functional class ≥ II and LVEF < 45%, remaining on 
treatment with ACEI or ARB and b-blockers (if not contrain-
dicated) at the recommended dose or maximal tolerated 
dose, who were enrolled from hospital clinics at two tertiary 
cardiology centres (University Hospital in Wroclaw and St. 
John Paul II Hospital in Poznan). We initially planned to re-
cruit patients with LVEF < 35% as per the guidelines [6], but 
because this threshold was too restrictive to ensure a sufficient 
sample size it was increased to < 45%. Finally, patients with 
LVEF > 35% represented 55% of the studied population. 
Exclusion criteria comprised permanent arrhythmias, includ-
ing atrial fibrillation (because of the confounding effect of 
heart rhythm irregularities on the accuracy of GLS measure-
ment), significant valvular and congenital heart disease, pri-
mary hepatic dysfunction, a serum potassium level exceeding 
5.0 mmol/L, an estimated glomerular filtration rate (eGFR) of 
less than 30 mL/min/1.73 m2 of body-surface area, a history 
of side-effects with spironolactone, and treatment with MRA 
or acute coronary syndromes within the preceding six months. 
All participants were informed of the purpose of the study 
and provided written informed consent. Investigations con-
formed with the Declaration of Helsinki and were approved 
by the Institutional Ethics Committee.
Study protocol
At baseline, the enrollees underwent physical examination, 
blood specimen collection, echocardiography, and treadmill 
exercise testing. A 25-mg dose of spironolactone once daily 
was added to the treatment regimen in each participant. 
Previous pharmacotherapy was maintained unchanged. To 
standardise the comparisons between the treatment regimens 
using different drugs, medication quantity was determined 
by a daily defined dose calculated as per World Health Or-
ganisation standards [15]. Patients’ status, compliance with 
the treatment, and serum electrolytes and creatinine were 
monitored at fortnightly visits during the first two months and 
then monthly, with more frequent controls in case of clini-
cal indications. After six months, the baseline investigations 
were repeated.
Echocardiography
Echocardiographic imaging was performed using standard 
equipment (Vivid e9, General Electric Medical Systems, 
Milwaukee, WI, USA) with a phased array 2.5 MHz multifre-
quency transducer. Cardiac dimensions, volumes, and wall 
thicknesses were measured according to standard recom-
mendations. Peak early (E) and late diastolic flow velocity (A), 
and deceleration time of early diastolic flow wave (DT) were 
obtained from the apical four-chamber view by pulsed-wave 
Doppler. The ratio of mitral inflow early diastolic velocity to 
peak early diastolic tissue velocity (e’) averaged from the septal 
and lateral sides of the mitral annulus (E/e’) was calculated to 
approximate LV filling pressure.
Myocardial deformation was assessed by a semi-automated 
two-dimensional speckle tracking technique (Echopac, GE 
Medical Systems, Horten, Norway) from the three apical 
views with temporal resolution of 60 to 90 frames/s. All echo-
cardiographic indices were averaged over three consecutive 
cardiac cycles.
Exercise testing
Each participant underwent symptom-limited exercise testing 
on a treadmill using a modified Bruce protocol. Exercise capac-
ity was evaluated in metabolic equivalents (METs) on the basis 
of the peak exercise intensity from treadmill speed and grade.
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Laboratory assays
Peripheral venous blood samples were drawn between 
08:00 and 09:00 h, after a 30-min rest in the supine posi-
tion, and were subsequently frozen at –70°C until assayed. 
A commercially available fluorescence immunoassay (Triage 
BNP Test, Biosite Diagnostics Inc., San Diego, CA, USA) was 
used to assess circulating B-type natriuretic peptide (BNP).
Estimated GFR was computed according to the Modifica-
tion of Diet in Renal Disease (MDRD) four-variable formula.
Statistical analysis
Data are presented as mean ± standard deviation. Intergroup 
comparisons were carried out using an unpaired two-sided 
Student t test for continuous variables and by c2 test for cat-
egorical variables. Homogeneity of variances was assessed 
by the Levene test. Longitudinal analyses were performed 
by a paired two-sided Student t test. Skewed variables were 
log-transformed before analysis. Logistic regression analysis 
was used to determine predictors and assess associations of 
improvement in exercise capacity at follow-up. The c-statistic 
was used to evaluate model performance. A receiver operator 
characteristic analysis was used to examine the ability of par-
ticular variables to predict improvement in exercise capacity at 
follow-up. Changes in particular parameters with intervention 
(∆) were calculated by subtracting the baseline value from 
the follow-up value and were expressed in the units of their 
measurements. All calculations were performed with standard 
statistical software (Statistica for Windows 12; StatSoft Inc., 
Tulsa, OK, USA). A p-value of 0.05 was considered statisti-
cally significant. 
RESULTS
Demographic and clinical characteristics
According to the degree of improvement in exercise capac-
ity at six months, the study sample was divided into two 
groups including subjects demonstrating an arbitrary increase 
in METs > 20% (IMPRpos) and ≤ 20% (IMPRneg) of the 
baseline value. The two subsets did not differ in terms of 
age, sex proportions, body mass index (BMI), prevalence of 
hypertension and ischaemic aetiology of HF, NYHA class dis-
tribution, HF duration, blood pressure, heart rate, lipidogram, 
diabetes control, drugs prescriptions and quantities, baseline 
exercise capacity and exercise time, or sodium, potassium, 
and haemoglobin levels. The IMPRpos group was charac-
terised by a higher prevalence of diabetes, more impaired 
renal function, and lower baseline BNP level (Tables 1, 2). 
A larger increase in METs after a six-month treatment with 
spironolactone in the IMPRpos group was accompanied 
by a more pronounced beneficial change in NYHA clas-
sification (Table 2). No significant intergroup differences 
were noted in BNP-level dynamics with treatment; however, 
the percentage of patients with improvement (decrease) of 
this biomarker was higher in the IMPRpos group (51 [75%] 
vs. 30 [58%]; p = 0.04). 
In agreement with previous studies employing aldoster-
one blockade, there was a slight but significant increase in 
serum potassium (p < 0.001 in both subgroups) and a slight 
reduction in renal function (p for the decline in eGFR 0.05 in 
the IMPRpos group and 0.02 in the IMPRneg group; Table 2).
Cardiac morphology and function
The two groups formed on the basis of clinical response to treat-
ment did not differ with respect to baseline values of cardiac 
functional and structural characteristics. At follow-up, patients 
from the IMPRpos group demonstrated significantly greater 
improvements in LV end-diastolic, LV end-systolic, and stroke 
volumes, left atrial volume, LVEF, GLS, and septal e’ velocity as 
compared with their peers from the IMPRneg subset (Table 3).
Prediction of functional improvement  
with spironolactone
Logistic regression analysis revealed that the independent 
determinants of > 20% increase in exercise capacity at 
follow-up were as follows: presence of diabetes, baseline BNP, 
and eGFR. Each subsequent parameter added to a previous 
model improved the predictive power for improvement in 
exercise capacity at six months; namely, adding baseline 
eGFR improved the model based on diabetes mellitus, and 
adding baseline BNP improved the model based on diabetes 
and eGFR (Fig. 1A). Other variables tested in the model were 
selected on the basis of anticipated association and included 
age, sex, blood pressure, BMI, baseline values of LVEF, GLS, 
E/e’, and tricuspid annular plane systolic excursion. No signifi-
cant association with changes in exercise capacity was found 
for a decrease in renal function with treatment. 
To relate our findings to the symptomatic improvement in 
exercise tolerance, an analogical sequential logistic regression 
analysis was performed, in which the dichotomous depen-
dent variable was defined as a post-treatment improvement 
in NYHA class vs. no improvement. Similarly to the exercise 
capacity-based analysis, the presence of diabetes and baseline 
BNP level were independent predictors of symptomatic treat-
ment benefit, whereas eGFR was of borderline significance 
in the final model (Fig. 1B). Seventy-five per cent of patients 
in the symptomatic improvement group demonstrated an 
increase in METs > 20%. The subsets with and without 
a positive symptomatic response to spironolactone did not 
differ in BNP-level dynamics at follow-up (–60 [–209; –13] 
pg/mL vs. –44 [–128; 18] pg/mL, p = 0.25); however, the 
former group exhibited a significantly greater increase in GLS 
(3.7% ± 2.2% vs. 1.6% ± 2.7%, p < 0.001). 
Receiver operator characteristic analysis showed that the 
utility of particular variables in predicting improvement in 
exercise capacity at six months increased progressively in the 
following order: BNP (area under the curve [AUC] 0.61), pres-
ence of diabetes (AUC 0.64), and eGFR (AUC 0.69; Fig. 2). 
However, it should be noted that the AUC values for the 
predictors were low.
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Table 1. Demographic and clinical characteristics of the patients with an increase in baseline exercise capacity > 20% (IMPRpos) 
and < 20% (IMPRneg)
IMPRpos (n = 68) IMPRneg (n = 52) p IMPRpos vs. IMPRneg
Age [years] 63.4 ± 11.9 60.4 ± 8.5 0.14
Male sex 50 (74) 38 (73) 0.96
Ischaemic aetiology of HF 54 (79) 42 (81) 0.89
LVEF > 35% 38 (56) 28 (54) 0.82
Heart failure duration [years] 3.70 ± 3.76 3.50 ± 2.95 0.75
Body mass index [kg/m2] 29.3 ± 5.2 28.0 ± 4.0 0.15
Hypertension 55 (81) 38 (73) 0.31
Diabetes mellitus 29 (43) 8 (15) 0.002
Renal dysfunction 24 (35) 7 (13) 0.007
CABG 3 (4) 3 (6) 0.74
Total cholesterol [mg/dL] 170.0 ± 35.3 164.0 ± 31.6 0.34
LDL-cholesterol [mg/dL] 99.7 ± 32.1 94.1 ± 28.3 0.32
HDL-cholesterol [mg/dL] 41.9 ± 7.1 40.6 ± 12.4 0.47
Triglycerides [mg/dL] 142.0 ± 51.9 146.4 ± 81.4 0.71
Haemoglobin A1c [%]* 5.85 ± 0.93 6.09 ± 1.29 0.56
Pharmacological treatment:
ACEIs/ARBs 68 (100) 51 (98) 0.26
b-blockers 67 (99) 51 (98) 0.85
Ivabradine 1 (1) 1 (2) 0.85
Diuretic agents 51 (75) 36 (69) 0.60
Daily defined dose:
ACEIs/ARBs 1.21 ± 0.52 1.31 ± 0.54 0.31
b-blockers 0.83 ± 0.28 0.76 ± 0.24 0.15
Loop diuretics 2.34 ± 1.26 2.40 ± 0.45 0.74
Data are shown as number (percentage) or mean ± standard deviation. Renal dysfunction was defined as estimated glomerular filtration rate  
< 60 mL/min/1.73 m2. *Comparison of haemoglobin A1c only in diabetic patients. ACEI/ARBs — angiotensin converting enzyme inhibitors/ 
/angiotensin receptor blockers; CABG — coronary artery bypass grafting; HDL — high-density lipoprotein; HF — heart failure; LDL — low-density 
lipoprotein; LVEF — left ventricular ejection fraction; Conversion to SI units are as follows: for cholesterol — multiply by 0.02586, for triglicerydes 
— multiply by 0.01129
Table 2. Baseline values and change during follow-up in blood pressure, laboratory, and exercise testing characteristics of the 
patients with an increase in baseline exercise capacity > 20% (IMPRpos) and < 20% (IMPRneg)





p IMPRpos  
vs. IMPRneg
IMPRpos IMPRneg p IMPRpos 
vs. IMPRneg
Systolic BP [mmHg] 115.0 ± 15.2 114.6 ± 15.1 0.89 0.5 ± 11.2 –0.7 ± 8.7 0.53
Diastolic BP [mmHg] 73.0 ± 8.1 71.7 ± 8.1 0.40 –3.0 ± 9.5 –1.1 ± 7.6 0.25
Heart rate [bpm] 73.2 ± 8.7 74.3 ± 8.3 0.48 –2.5 ± 8.4 –1.4 ± 6.6 0.43









BNP [pg/mL] 132 (79–341) 279 (121–474) 0.04 –51 (–158 – 1) –47 (–96 – 17) 0.71
Creatinine [mg/dL] 1.10 ± 0.25 1.01 ± 0.21 0.04 0.04 ± 0.20 0.07 ± 0.18 0.40
eGFR [mL/min/1.73 m2] 68.1 ± 14.8 78.0 ± 17.9 0.002 –3.1 ± 10.4 –5.6 ± 16.0 0.31
Haemoglobin [g/dL] 11.6 ± 2.9 10.9 ± 2.6 0.18 0.1 ± 0.7 0.1 ± 0.6 0.68
Sodium [mmol/L] 138.9 ± 2.4 138.7 ± 2.2 0.64 0.7 ± 2.6 0.3 ± 2.2 0.43
Potassium [mmol/L] 4.2 ± 0.3 4.3 ± 0.3 0.21 0.3 ± 0.4 0.3 ± 0.3 0.40
METs 5.3 ± 2.5 6.1 ± 2.5 0.09 3.0 ± 1.4 0.0 ± 0.8 < 0.001
METs [% predicted] 67.6 ± 31.0 74.5 ± 17.4 0.18 39.4 ± 20.1 0.1 ± 9.3 < 0.001
Exercise time [s] 251 ± 144 292 ± 103 0.09 163.0 ± 112 6 ± 54 < 0.001
Data are shown as number (percentage), mean ± standard deviation or median (interquartile range); BP — blood pressure; BNP — B-type natriuretic 
peptide; eGFR — estimated glomerular filtration rate; METs — metabolic equivalents; NYHA — New York Heart Association
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Table 3. Baseline values and change during follow-up in cardiac structural and functional characteristics of the patients with an 
increase in baseline exercise capacity > 20% (IMPRpos) and < 20% (IMPRneg)







IMPRpos IMPRneg p IMPRpos 
vs. IMPRneg
LV end-diastolic dimension [mm] 61.1 ± 8.2 60.4 ± 7.3 0.62 –0.8 ± 8.7 –0.6 ± 4.6 0.88
Septal wall [mm] 11.7 ± 2.1 11.2 ± 2.0 0.20 –0.5 ± 1.8 0.0 ± 1.5 0.14
Posterior wall [mm] 10.2 ± 2.2 9.7 ± 1.9 0.21 –0.2 ± 1.7 0.1 ± 1.3 0.31
LV mass index [g/m2] 135.4 ± 32.6 126.9 ± 33.4 0.18 –5.6 ± 22.3 –1.8 ± 16.0 0.30
Basal RV dimension [mm] 38.6 ± 4.8 37.7 ± 5.1 0.33 –0.1 ± 2.6 0.5 ± 2.5 0.22
LV end-diastolic volume [mL/m2] 68.4 ± 21.6 71.9 ± 27.7 0.44 –3.8 ± 13.4 0.4 ± 17.3 0.15
LV end-systolic volume [mL/m2] 43.3 ± 17.7 44.8 ± 20.5 0.66 –8.7 ± 13.4 –1.4 ± 14.4 0.005
Stroke volume index [mL/m2] 25.1 ± 8.2 27.1 ± 9.3 0.32 5.0 ± 6.5 1.8 ± 5.5 0.006
LA volume index [mL/m2] 37.7 ± 15.0 34.0 ± 16.0 0.21 –3.0 ± 7.9 1.6 ± 10.4 0.007
LV ejection fraction [%] 37.7 ± 6.8 37.2 ± 7.1 0.70 5.7 ± 7.4 3.0 ± 5.8 0.03
LV global longitudinal strain [%] 11.3 ± 3.2 12.2 ± 3.2 0.15 3.6 ± 2.6 1.6 ± 2.3 < 0.001
E/A ratio 0.98 ± 0.50 0.93 ± 0.44 0.58 0.00 ± 0.52 0.03 ± 0.39 0.74
E-wave deceleration time [ms] 207 ± 68 222 ± 82 0.30 10 ± 81 –7 ± 52 0.20
Septal e’ velocity [cm/s] 5.3 ± 1.5 5.0 ± 2.2 0.39 0.3 ± 1.2 –0.3 ± 1.3 0.008
E/e’ 14.6 ± 6.1 13.9 ± 5.9 0.52 –1.9 ± 7.3 –0.3 ± 4.6 0.18
TAPSE [mm] 20.3 ± 4.4 20.9 ± 3.9 0.43 0.6 ± 3.9 –0.2 ± 3.0 0.21
Data are shown as mean ± standard deviation. LA — left atrial; LV — left ventricular; RV — right ventricular; TAPSE — tricuspid annular plane 
systolic excursion
Figure 1. Predictive value of diabetes, renal function, and B-type natriuretic peptide (BNP) for > 20% improvement in exercise 
capacity at six months (A) and for improvement in New York Heart Association class at six months (B) by logistic regression  
models; CI — confidence interval; DM — diabetes mellitus; eGFR — estimated glomerular filtration rate; OR — odds ratio
A B
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Associations of changes in LV functional  
characteristics with improvement  
in exercise capacity
Logistic regression analysis demonstrated that among LV sys-
tolic and diastolic parameters, only improvement in GLS was 
independently associated with an > 20% increase in exercise 
capacity at follow-up (Table 4).
Adherence and side effects
All enrolled patients completed the study. In four participants 
(two in each subgroup), the dose of spironolactone had to 
be reduced to 25 mg every other day due to hyperkalae-
mia > 5.5 mmol/L. Mild gynaecomastia developed in one 
male patient but did not lead to drug discontinuation. No 
other adverse effects or complications were reported.
DISCUSSION
This study demonstrates that improvement in exercise capac-
ity in a clinically stable population with HFrEF in response 
to the addition of spironolactone to standard treatment is 
more evident in the presence of diabetes, decreased renal 
function and lower BNP level, and improvement in GLS may 
be an indicator of this beneficial effect of MRA. Accordingly, 
symptomatic HFrEF patients with diabetes and kidney dis-
ease, despite being at increased risk for the development of 
hyperkalaemia and worsening renal performance, should be 
considered for this therapeutic strategy. 
Clinical determinants of response  
to aldosterone blockade
The mechanisms behind the clinical benefit imparted by 
MRA in HF are not entirely clear. Previous large, randomised 
trials demonstrated that the prognostic benefits of MRA were 
achievable over a wide spectrum of clinical and pathophysi-
ological derangements; however, the magnitude of the effect 
of this treatment might differ between some subsets [1–3]. 
The current study identified factors promoting improvement 
in exercise tolerance with a six-month spironolactone therapy 
in the HF population with LVEF < 45%. 
Diabetes mellitus is recognised as a major risk factor 
for adverse outcomes, as well as the development of hyper-
kalaemia and renal insufficiency in HF [8]. However, patients 
with diabetes in the present study were more likely to exhibit 
a greater post-treatment increase in exercise capacity than 
their non-diabetic counterparts. In the pathophysiological 
milieu of metabolic disturbances, the cardiovascular system 
may be more prone to the detrimental influence of aldos-
terone and thereby respond more positively to aldosterone 
blockade. The finding of the amplification of the MRA effect 
in diabetes is in line with the post hoc analysis from the 
EPHESUS trial reporting a higher absolute risk reduction of 
the composite of cardiovascular death and hospitalisation in 
the diabetic cohort [16]. 
Figure 2. Receiver operating characteristic curves of B-type 
natriuretic peptide (A), diabetes (B), and estimated glome-
rular filtration rate (C) in predicting > 20% improvement in 
exercise capacity at six months; AUC — area under the curve; 





Rafał Dankowski et al.
1332
Renal dysfunction, both present at baseline and devel-
oping during treatment, contributes to increased risk in HF 
[8]. Despite a potential GFR-depressing effect of MRA, HF 
patients with mild to moderate renal insufficiency (eGFR 
30–60 mL/min/1.73 m2) are beneficiaries of therapy with 
aldosterone blockade [8, 17]. Our analysis revealed that 
decreased pre-treatment renal function was associated with 
a greater functional improvement at six months. This is con-
sistent with the absolute clinical risk reduction in the RALES 
trial, which was most pronounced in patients with reduced 
GFR [17], as well as with the results of a small study showing 
improvements in LV structural and functional characteristics 
with MRA in chronic kidney disease [18, 19]. The explanation 
for the favourable effects of MRA in the context of reduced 
renal function might be that specific pathophysiological fea-
tures promote a positive response to aldosterone-antagonising 
therapy in this setting. Up-regulation of the renin–angioten-
sin–aldosterone system and a subsequent aldosterone-me-
diated cardiac and renal injuries might provide a substrate 
for MRA to induce beneficial alterations resulting in clinical 
improvements [17, 20].
The larger post-treatment increment in exercise capacity 
in the current study was linked with lower BNP levels at a base-
line assessment. BNP and N-terminal pro–BNP (NT-proBNP) 
have been shown to be major prognosticators in HFrEF, as 
well as markers mirroring the treatment effects, also with MRA 
[5, 21, 22]. We did not demonstrate a higher average decline 
in BNP levels in the subset that benefited more from taking 
spironolactone, but on an individual basis, a higher propor-
tion of patients from this group experienced the decrease in 
BNP as compared with their peers who had a lower degree 
of functional improvement. It can be hypothesised that lower 
pre-treatment BNP levels might reflect a higher potential for 
reversibility of cardiovascular abnormalities. The reasons for 
this are speculative, and the amount of myocardial fibrosis, 
which has been shown to be associated with the level of 
natriuretic peptides even in the subclinical disease, should be 
considered [23]. This notion is not discrepant with the finding 
that the groups of better and poorer responders to treatment 
did not differ significantly in the baseline LV impairment, 
because the degree of cardiac fibrosis may not correlate with 
LV functional indices in HFrEF [24]. From a practical point of 
view, the obtained results encourage the early implementa-
tion of spironolactone therapy in patients with stable HF and 
relatively low BNP values, especially if they have diabetes, 
because in this group of patients one can expect the greatest 
functional improvement after using this drug.
LV remodelling and contribution from GLS
The addition of MRA to therapy generated favourable 
changes in LV structural and functional remodelling, which 
were more pronounced in the subset with a greater increase 
in exercise capacity. Both LV volumetric improvement (with 
an increase in ejection fraction as a consequence) and myo-
cardial deformation improvement were demonstrated, but 
only the augmentation of GLS was significantly associated 
with a more apparent regression of exercise intolerance. 
Despite strong pathophysiological underpinnings, the direct 
relationship between improvements in cardiac function and 
clinical benefits has not been convincingly shown in previous 
interventions with MRA in HFrEF [4]. One of the reasons for 
this might be the use of echo-derived LVEF having a number 
of limitations that decrease the sensitivity and appropriateness 
of assessment [11]. This study showed that GLS, characterised 
by avoidance of geometric assumptions, less variability and 
load-dependence, and higher sensitivity to subtle changes, 
might be a better tool to provide incremental information on 
the translation of myocardial improvements into clinical gains. 
Limitation of the study
The results of this study should be interpreted in view of 
several limitations. First, the study population does not 
satisfy the newly-proposed definition of HFrEF because of 
the inclusion of a number of individuals currently classified 
as having HF with mid-range ejection fraction. Therefore, 
the extrapolation of our findings to patients with a more 
severely depressed ejection fraction should be made cau-
tiously. Second, the estimated GFR was calculated on the 
basis of the MDRD formula, which may be less accurate for 
eGFR > 60 mL/min/1.73 m2. Third, the exclusion of patients 
with atrial fibrillation might restrict the external validity of 
our investigations. Fourth, we did not use a core-lab for 
Table 4. Associations of changes from baseline to follow-up in left ventricular systolic and diastolic parameters with > 20% 
improvement in exercise capacity at six months
Parameter Unadjusted Model with diabetes, eGFR, and BNP
OR 95% CI p OR  95% CI p
∆ GLS 1.40 1.10–1.37 0.005 1.40 1.06–1.84 0.019
∆ LVEF 1.06 0.99–1.15 0.10 1.03 0.93–1.14 0.53
∆ E/e’ 0.96 0.88–1.04 0.31 0.97 0.88–1.06 0.45 
∆  — value at follow-up minus value at baseline; CI — confidence interval; BNP — B-type natriuretic peptide; GLS — global longitudinal  
deformation; eGFR — estimated glomerular filtration rate; LVEF — left ventricular ejection fraction; OR — odds ratio
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echocardiographic analyses; however, a high reproducibil-
ity of measurements between the two participating centres 
(Supplementary material — see journal website) suggests 
that this could not have been a reason for data misinterpreta-
tion. Finally, because all the study participants were of Cau-
casian race, the applicability of our findings to other ethnic 
groups is uncertain.
In conclusion, the coexistence of diabetes mellitus and/or 
impaired renal function — conditions associated with an 
increased risk of adverse clinical outcomes and detrimental 
side-effects of MRA — favours greater post-treatment incre-
ments in exercise capacity in response to aldosterone blockade 
added on top of optimal medical therapy in clinically stable 
HFrEF patients. These high-risk subgroups require, however, 
very strict biochemical control and reconsideration of MRA 
that are more selective than spironolactone and possess 
a better safety profile in terms of undesirable metabolic 
and potassium-increasing effects. GLS reflects the changes 
in cardiac mechanics closely associated with the regression 
of exercise limitation and might be suitable to monitor the 
improvements in LV function with treatment.
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WHAT IS NEW?
Despite the increasing use of mineralocorticoid receptor antagonism (MRA) in heart failure, the factors influencing the 
effectiveness of this therapeutic option remain insufficiently defined. This issue may be important for decision-making 
especially in patients with renal disorders and/or the propensity to develop hyperkalaemia — conditions associated with an 
increased risk of adverse clinical outcomes and detrimental side-effects of MRA. Our study demonstrated that improvement 
in exercise capacity in a clinically stable population with heart failure with reduced ejection fraction (HFrEF) in response 
to the addition of spironolactone to standard treatment is more evident in the presence of diabetes and decreased renal 
function, and improvement in left ventricular longitudinal deformation is a contributor to this beneficial effect of MRA. 
Accordingly, symptomatic HFrEF patients with diabetes and kidney disease, despite being at higher risk for the develop-
ment of hyperkalaemia and worsening renal performance, should be considered for this therapeutic strategy.
Cite this article as: Dankowski R, Kotwica T, Szyszka A, et al. Determinants of the beneficial effect of mineralocorticoid receptor antagonism 
on exercise capacity in heart failure with reduced ejection fraction. Kardiol Pol. 2018; 76(9): 1327–1335, doi: 10.5603/KP.a2018.0128.
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